Two patients with the same diagnosis may respond differently to the same treatment. Precision medicine seeks to understand those differences and use them to guide care.

The evidence can be difficult to connect. Genomic data, prior treatments, other health conditions, and clinical outcomes often live in separate systems. AI can help researchers analyze these sources together.

The Patient Stratification Challenge

Patient stratification groups people by characteristics that may affect treatment response. In cancer, for example, tumors with the same broad diagnosis can have different molecular drivers.

Relevant information may include:

  • Genomic data: Mutations, gene expression, and copy number changes
  • Proteomic data: Protein levels and modifications
  • Clinical data: Disease history, other conditions, and prior treatments
  • Demographic and exposure data: Characteristics that may help explain differences in outcomes

Researchers need to determine which patterns are useful and whether they hold up in other patient groups.

AI-Powered Stratification

AgentCures considers patient differences during drug development. The agent can help analyze molecular data, identify candidate biomarkers, and build models of treatment response.

Those analyses can inform target selection, trial eligibility criteria, and plans for companion diagnostics. Keeping them connected to the research record lets scientists review how a proposed patient group was defined.

What It Means for Patients

A useful biomarker can help identify people more likely to benefit from a treatment. It may also help avoid exposing people to a trial when their biology gives little reason to expect a response.

The goal is a treatment decision supported by evidence about the patient and the disease.

The Clinical Trial Advantage

Selecting a biologically relevant patient group can make a trial’s question more precise. It can also change the sample size, recruitment needs, and interpretation of the result.

AgentCures explores candidate biomarkers during target selection and trial planning. Teams can compare designs and examine whether the proposed criteria are practical and supported by data.

Scaling Precision Medicine

Larger datasets make it possible to study more differences between patients. They also make data quality and model evaluation more important.

AI can help process those datasets, update analyses, and compare proposed stratification strategies. Scientists still need to assess whether a model’s predictions are useful for the population a program intends to serve.

From Bench to Bedside

We’re building patient stratification into the same workflow as target selection, molecular design, and trial simulation. This gives the team a way to consider who a treatment might help while the program is still taking shape.